Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests AHB-137 injection in adults with chronic hepatitis B and low HBsAg

Tests AHB-137 injection in adults with chronic hepatitis B and low HBsAg.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Key facts

Where
Beijing, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou, Jilin City, Nanning, Shenzhen, Xiamen, and Zhengzhou, ChinaSee the 11 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic hepatitis B who have low levels of hepatitis B surface antigen (HBsAg). It tests the safety and effect of AHB-137 injection.

Age
18-65 years, including 18 and 65.
Sex
All sexes can join.
Disease stage
Chronic hepatitis B with low HBsAg levels. HBsAg or HBV DNA must have been positive for at least 6 months.
Earlier treatment
Earlier medicines must meet the trial's requirements. Use of prohibited medicines is not allowed.
Biomarker or test result
HBsAg or HBV DNA positive for at least 6 months. HBsAg, HBV DNA and liver function results must meet the requirements.

Main reasons for not taking part

  • Other liver disease
  • HCV RNA, HIV antibody or syphilis positive
  • Serious infection needing intravenous treatment
  • History of cancer or cancer being checked
  • Taking part in another clinical trial

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT07137910, who can take part

Where in China

  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Changzhou, JiangsuHospital not named in the registryNot yet recruiting
  • Chengdu, SichuangHospital not named in the registryNot yet recruiting
  • Chongqing, Chongqing MunicipalityHospital not named in the registryNot yet recruiting
  • Guangzhou, GuangdongHospital not named in the registryNot yet recruiting
  • Hangzhou, ZhejiangHospital not named in the registryNot yet recruiting
  • Jilin City, JilinHospital not named in the registryTaking people
  • Nanning, GuangxiHospital not named in the registryTaking people
  • Shenzhen, GuangdongHospital not named in the registryNot yet recruiting
  • Xiamen, FujianHospital not named in the registryTaking people
  • Zhengzhou, HenanHospital not named in the registryNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Ausper Biopharma Co., Ltd.
Trial code
NCT07137910
Record updated
5 August 2026
Original description
This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.Read full original descriptionShow less

An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.

Inclusion: Voluntarily participate in the study and sign the informed consent form; 18-65 years of age (including boundary values) ; Body mass index met the requirements; Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months; Meet the relevant requirements for prior medications; HBsAg and HBV DNA and liver function indicators meet the requirements; Effective contraception as required.

Exclusion: Participants with recent major trauma or major surgery, or planning surgery; Those who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study; Prior/current use of prohibited medications; Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection; Associated liver disease; Any serious infection other than CHB infection requires intravenous anti-infective therapy; HCV RNA positive, HIV antibody positive, syphilis positive; Diseases associated with vascular inflammatory conditions; History of malignancy or ongoing assessment of possible malignancy; History of allergies, or allergic constitution; Abnormal laboratory results; QT interval corrected heart rate (Fridericia method) abnormal; Inappropriate for participation in this trial as judged by the investigator.

ClinicalTrials.gov NCT07137910